Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 6/2013

01-07-2013 | Original Article

Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma

Authors: Ping-Wun Huang, Shih-Chung Tsai, Tsai-Yueh Luo, Chia-Hung Kao, Wan-Yu Lin

Published in: Annals of Nuclear Medicine | Issue 6/2013

Login to get access

Abstract

Objective

In our recent study, we developed a new radiopharmaceutical (Re-188 MN-16ET lipiodol) with encouraging results for the treatment of liver malignancy. In this study, we further evaluated the therapeutic efficacy of this radiopharmaceutical by measuring tumor response and survival times in rats with liver tumors after intra-hepatic arterial injection of Re-188 MN-16ET lipiodol.

Methods

Twelve male rats bearing hepatic tumors were divided into three groups. Group 1 received an intra-hepatic arterial injection of 18.5 MBq Re-188 MN-16ET lipiodol; Group 2 received lipiodol and Group 3 received normal saline. Tumor size was measured by liver sonography before injection, at 2, 4, and 8 weeks after injection. Survival time and response rate were calculated.

Results

All rats showed good response and survived over 60 days in Group 1 while all rats showed poor response in Group 2 and Group 3 with only 25 % of rats in Group 2 and none (0 %) in Group 3 survived over 60 days. The p value was 0.0067 between Group 1 and Group 3; 0.04 between Group 1 and Group 2; and 0.034 between Group 2 and Group 3.

Conclusion

Re-188 MN-16ET lipiodol has good potential for the treatment of hepatoma.
Literature
1.
Jeong JM, Kim YJ, Lee YS, Ko JI, Son M, Lee DS, et al. Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol. 2001;28:197–204.PubMedCrossRef
2.
Wang SJ, Lin WY, Chen MN, Hsieh BT, Shen LH, Tsai ZT, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med. 1996;23:13–7.PubMedCrossRef
3.
Luo TY, Hsieh BT, Wang SJ, Lin WY, Lee TW, Shen LH, et al. Preparation and biodistribution of rhenium-188 ECD/lipiodol in rats following hepatic arterial injection. Nucl Med Biol. 2004;31:671–7.PubMedCrossRef
4.
Garin E, Denizot B, Noiret N, Lepareur N, Roux J, Moreau M, et al. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Commun. 2004;25:1007–13.PubMedCrossRef
5.
Sundram FX, Jeong JM, Zanzonico P, Bernal P. Trans-arterial rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA-sponsored multi-centre phase I study. World J Nucl Med. 2002;1:5–11.
6.
Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys. 2007;69:1448–55.PubMedCrossRef
7.
Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram FX, Kumar A, et al. International Atomic Energy Agency-Sponsored Multination Study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin Nucl Med. 2008;38:S40–5.PubMedCrossRef
8.
Lambert B, Bacher K, Defreyne L. Rhenium-188 based radiopharmaceuticals for treatment of liver tumors. Q J Nucl Med Mol Imaging. 2009;53:305–10.PubMed
9.
Lee YS, Jeong JM, Kim YJ, Chang YS, Lee HJ, Son M, et al. Development of acetylated HDD kit for preparation of 188Re-HDD/Lipiodol. Appl Radiat Isot. 2007;65:64–9.PubMedCrossRef
10.
Tang IC, Luo TY, Liu SW, Chan SH, Kung HC, Peng CL, et al. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model. Nucl Med Biol. 2011;38:1043–52.PubMedCrossRef
11.
Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985;154:19–24.PubMed
12.
Raoul JL, Duvauferrier R, Bourguet P, Bretagne JF, Coornaert S, Darnault P, et al. Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol. J Radiol. 1986;67:797–801.PubMed
13.
Kobayashi H, Hidaka H, Kajiya Y, Tanoue P, Inoue H, Ikeda K, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn. 1986;27:139–47.
14.
Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127:S218–24.PubMedCrossRef
15.
McCann JW, Larkin AM, Martino LJ, Eschelman DJ, Gonsalves CF, Brown DB. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? J Vasc Interv Radiol. 2012;23:661–7.PubMedCrossRef
Metadata
Title
Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma
Authors
Ping-Wun Huang
Shih-Chung Tsai
Tsai-Yueh Luo
Chia-Hung Kao
Wan-Yu Lin
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 6/2013
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-013-0717-5

Other articles of this Issue 6/2013

Annals of Nuclear Medicine 6/2013 Go to the issue

Original Article

Scintigraphic comparison of renal ischemia–reperfusion injury models in rats: correlations with biochemical and histopathological findings

Short Communication

Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening

Original Article

The clinical value of tumor FDG uptake for predicting axillary lymph node metastasis in breast cancer with clinically negative axillary lymph nodes

Original Article

Myocardial sympathetic innervation, function, and oxidative metabolism in non-infarcted myocardium in patients with prior myocardial infarction

Original Article

Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer

Original Article

Underestimation of the ejection fraction using the quantitative gated SPECT for patients with myocardial hypertrophy